 |
 |
|
SUNDAY, DECEMBER 7, 2003
|
All
day:
|
Arrival and Registration |
|
MONDAY, DECEMBER 8, 2003
|
| 8:30
- 10:30 |
Opening Ceremony
|
|
Plenary Session I:
THE DRUG-ELUTING STENT ERA: UPDATE AND IMPACT
|
|
Drug-Eluting Stents…Technical Update
|
|
Thematic case # 1
|
|
Drug-Eluting Stents…Clinical Update
|
|
Thematic case # 2
|
|
Debate:
THE CLINICAL APPLICATION OF DRUG-ELUTING STENTS
- The Dominant CAD Revascularization Strategy
- Surgery is Still the Preferred Option
|
| 10:30
- 11:00 |
Coffee Break
|
| 11:00
- 12:30 |
Concurrent Sessions:
|
| Session
C1: |
DRUG-ELUTING STENTS: CLINICAL TRIALS, DRUGS, CONCEPTS AND
CONTROVERSIES
|
| Session
C2: |
ANGIOGENESIS, MYOGENESIS AND GENE THERAPY
|
| Session
C3: |
COMPLEX CORONARY LESIONS (DIFFUSE DISEASE, SMALL VESSELS,
BIFURCATIONS, CTOS, LM DISEASE AND SVGS)
|
| 12:30
- 14:00 |
Scientific Luncheons:
|
| Lunch
Session 1: |
CAROTID STENTING: THE PREFERRED APPROACH
|
| Lunch
Session 2: |
OPTIMAL USE OF VASCULAR BRACHYTHERAPY IN A DRUG-ELUTING
STENT WORLD
|
| 14:00
- 16:00 |
Plenary Session II:
VULNERABLE PLAQUE, ADJUNCTIVE PHARMACOLOGY AND ACUTE CORONARY
SYNDROMES
|
|
Thematic case #3
|
|
THE “INFLAMMATION” THEORY OF ATHEROSCLEROSIS, ACUTE ISCHEMIC
SYNDROMES AND RESTENOSIS
|
|
THE VULNERABLE PLAQUE CONTROVERSY: DIAGNOSTIC MODALITIES
AND THERAPEUTIC POSSIBILITIES
|
|
Thematic case # 4
|
|
ADJUNCTIVE PHARMACOLOGY IN PCI: ANTI-PLATELET AGENTS, THROMBIN
INHIBITORS, IIb/IIIa INHIBITORS AND BEYOND
|
|
INNOVATIVE PHARMACOLOGIC AND MECHANICAL THERAPIES FOR ACUTE
MYOCARDIAL INFARCTION
|
| 16:00
- 16:30 |
Coffee Break
|
| 16:30
- 17:30 |
Concurrent Sessions:
|
| Session
C4: |
A “MINI” VULNERABLE PLAQUE SUMMIT
|
| Session
C5: |
CORONARY IMAGING AND PHYSIOLOGY (CT ANGIOGRAPHY, MR OCT,
IVUS, FER, ETC)
|
Session
C6:
|
INTERVENTIONAL DEVICE ENHANCEMENTS (STENTS, DISTAL PROTECTION,
VASCULAR CLOSURE, ETC)
|
|
TUESDAY, DECEMBER 9, 2003
|
| 08:30
- 10:30 |
Plenary Session III:
ENDOVASCULAR INTERVENTIONS
|
|
GLOBAL VASCULAR INTERVENTION: THE ROLE OF THE INTERVENTIONAL
CARDIOLOGIST IN NON-CORONARY VASCULAR DISEASE
|
|
Thematic case # 5
|
|
CAROTID STENTING HAS ARRIVED! THE FAVORED THERAPY FOR CAROTID
BIFURCATION DISEASE
|
|
Thematic Case # 6
|
|
CONTROVERSIES IN AAA ENDOGRAFT THERAPIES…DEFINING APPROPRIATE
CURRENT AND FUTURE CLINICAL APPLICTIONS
|
|
DIAGNOSIS AND INTERVENTIONAL MANAGEMENT OF RENAL ARTERY
STENOSIS
|
| 10:30
- 11:00 |
Coffee Break
|
| 11:00
- 12:30 |
Concurrent Sessions:
|
| Session
C7: |
EMERGING TECHNOLOGIES FROM ISRAEL
|
| Session
C8: |
CLINICAL CASE REVIEW SESSION OF INTERVENTIONAL COMPLICATIONS:
MY WORST NIGHTMARES
|
| Session
C9: |
NON CORONARY INTERVENTIONS
|
| 12:30
- 14:00 |
Scientific Luncheons:
|
| Lunch
Session 3: |
DRUG-ELUTING STENTS: A “TRANSFORMING” TECHNOLOGY
|
| Lunch
Session 4: |
OPTIMAL USE OF ANTI-PLATELET THERAPY IN CARDIOVASCULAR DISEASE
|
| Lunch
Session 5: |
SPECIAL LUNCHEON FOR PARAMEDICAL CARDIOVASCULAR SPECIALISTS
|
| 14:00
- 15:30 |
Special Plenary Session IV:
CLINICAL MANAGEMENT BEYOND THE CATHETERIZATION LABORATORY
(FOR INTERNISTS, FAMILY PRACTITIONERS AND COMMUNITY PHYSICIANS)
|
|
LONG TERM ANTIPLATELET TREATMENT FOLLOWING CORONARY INTERVENTIONS
|
|
Thematic case #7
|
|
AN AGGRESSIVE RISK REDUCTION STRATEGY FOR PATIENTS FOLLOWING
PCI
|
|
Thematic case #8
|
|
ROUTINE FOLLOW-UP VERSUS CLINICALLY DRIVEN TESTS
|
| 15:30
- 16:00 |
Coffee Break
|
| 16:00
- 17:30 |
Concluding Session:
THE FUTURE INNOVATIONS IN INTERVENTIONAL VASCULAR MEDICINE
|
|
Thematic case #9
|
|
DEVICE-BASED THERAPY FOR CHF: CONCEPT AND EXECUTION
|
|
COPING WITH THE BIOTECHNOLOGY REVOLUTION: FROM TISSUE ENGINEERING
CONCEPTS TO CELL THERAPY TO BIODEGRADABLE STENTS
|
|
Thematic case #10
|
|
PERCUTANEOUS HEART VALVE THERAPIES…FOLLY OR PRACTICAL THERAPY
|
|
INNOVATIVE MOLECULAR BIOLOGY APPROACHES TO ANGIOGENESIS,
MYOGENESIS AND CARDIAC ARRHYTHMIAS
|
|
|
